|
Post by mnkdfann on Jun 2, 2019 9:10:32 GMT -5
A very nice article, except the last few paragraphs are way out of date when it comes to Brazil's economy. That's clear from the old data it cites. Brazil has suffered since the commodity bubble collapsed, and may not be as attractive to foreign companies as it was a decade ago. www.bloomberg.com/news/articles/2019-05-03/brazil-industry-s-march-drop-boosts-odds-of-economy-shrinking"The Brazilian economy has suffered with a disappointing recovery since emerging from a deep recession two years ago. Record-low interest rates haven’t provided the hoped-for boost to the industrial sector, which since 2017 hasn’t once posted back-to-back months of growth. With the government fiscally strapped, a wave of private-sector investment is needed to accelerate growth, but confidence has wavered since President Jair Bolsonaro assumed power." Interestingly, I guess Mannkind signed the Brazil deal in May 2017, when Brazil was coming out of a recession and things were probably looking good. Since then the economy in Brazil reversed, and it now may be heading back to a recession. Timing!
|
|
|
Post by peppy on Jun 2, 2019 9:41:35 GMT -5
A very nice article, except the last few paragraphs are way out of date when it comes to Brazil's economy. That's clear from the old data it cites. Brazil has suffered since the commodity bubble collapsed, and may not be as attractive to foreign companies as it was a decade ago. www.bloomberg.com/news/articles/2019-05-03/brazil-industry-s-march-drop-boosts-odds-of-economy-shrinking"The Brazilian economy has suffered with a disappointing recovery since emerging from a deep recession two years ago. Record-low interest rates haven’t provided the hoped-for boost to the industrial sector, which since 2017 hasn’t once posted back-to-back months of growth. With the government fiscally strapped, a wave of private-sector investment is needed to accelerate growth, but confidence has wavered since President Jair Bolsonaro assumed power." Interestingly, I guess Mannkind signed the Brazil deal in May 2017, when Brazil was coming out of a recession and things were probably looking good. Since then the economy in Brazil reversed, and it now may be heading back to a recession. Timing!
|
|
|
Post by prcgorman2 on Jun 2, 2019 10:33:17 GMT -5
Peppy, what are the numbers you posted?
The article on the Brazilian regulatory agency was interesting, and MNHoldem’s post of the reguatory process was great. Given the price regulation and uncertainty of whether Afrezza would be on the governmnent formulary, I can see why MC commented about India and Brazil as being good for defraying Afrezza’s manufacturing costs.
|
|
|
Post by gcozz on Jun 2, 2019 11:20:33 GMT -5
Those are U.S. market interest rates for the 3 month to 30 year Treasuries.
|
|
|
Post by pat on Jun 2, 2019 11:20:34 GMT -5
Looks like the US Treasury yield curve. When short term rates are above longer term rates it’s called an “inverted yield curve”. Usually points to a pending recession. That’s the buzz lately. Although nobody knows what the heck is going on. Inflation below fed target. Labor markets tight. Growth still good. Tariff war(s).
Kind of random to throw it out during a discussion of Brazil?.
|
|
|
Post by peppy on Jun 2, 2019 11:51:37 GMT -5
Looks like the US Treasury yield curve. When short term rates are above longer term rates it’s called an “inverted yield curve”. Usually points to a pending recession. That’s the buzz lately. Although nobody knows what the heck is going on. Inflation below fed target. Labor markets tight. Growth still good. Tariff war(s). Kind of random to throw it out during a discussion of Brazil?. yes, but I like the people on this board and I want them to know and see.
|
|
|
Post by sportsrancho on Jun 3, 2019 7:02:09 GMT -5
|
|
|
Post by sportsrancho on Jun 7, 2019 23:35:55 GMT -5
ST...$MNKD from Rose...."Thank you for your inquiry. You are correct. In Brazil, Afrezza is designated as an ultra rapid-acting mealtime insulin. In the US, Afrezza is designated as a rapid-acting inhaled insulin. We continue to pursue reclassification or creation of a new category with scientific data from trials."
|
|
|
Post by centralcoastinvestor on Jun 8, 2019 0:42:51 GMT -5
ST...$MNKD from Rose...."Thank you for your inquiry. You are correct. In Brazil, Afrezza is designated as an ultra rapid-acting mealtime insulin. In the US, Afrezza is designated as a rapid-acting inhaled insulin. We continue to pursue reclassification or creation of a new category with scientific data from trials." That is great news. This puts it in another category in Brazil. I would assume that will help with pricing since Afrezza will not be compared to the already crowded field of rapid-acting insulin. We will see.
|
|
|
Post by mnkdfann on Jun 8, 2019 8:25:58 GMT -5
ST...$MNKD from Rose...."Thank you for your inquiry. You are correct. In Brazil, Afrezza is designated as an ultra rapid-acting mealtime insulin. In the US, Afrezza is designated as a rapid-acting inhaled insulin. We continue to pursue reclassification or creation of a new category with scientific data from trials." That is great news. This puts it in another category in Brazil. I would assume that will help with pricing since Afrezza will not be compared to the already crowded field of rapid-acting insulin. We will see. I'm just wondering, if Afrezza could get a better designation in Brazil than it did in the U.S., have none of its competitors done the same?
|
|
|
Post by prcgorman2 on Jun 8, 2019 9:00:52 GMT -5
Competiitor to Afrezza? Or Mannkind? What is the competition to Afrezza? Intravenous administration of human insulin at a hospital?
|
|
|
Post by celo on Jun 8, 2019 9:25:14 GMT -5
That is great news. This puts it in another category in Brazil. I would assume that will help with pricing since Afrezza will not be compared to the already crowded field of rapid-acting insulin. We will see. I'm just wondering, if Afrezza could get a better designation in Brazil than it did in the U.S., have none of its competitors done the same? Great job by Rose to announce on stock twits that Afrezza received Ultra Rapid designation in Brazil. Rose? This is major news. There is a massive population in the USA that doesn't know there is an ultra rapid product in existence, including the ADA. This should be shoved in every endo's face.
|
|
|
Post by shawnonafrezza on Jun 8, 2019 9:59:30 GMT -5
I'm just wondering, if Afrezza could get a better designation in Brazil than it did in the U.S., have none of its competitors done the same? Great job by Rose to announce on stock twits that Afrezza received Ultra Rapid designation in Brazil. Rose? This is major news. There is a massive population in the USA that doesn't know there is an ultra rapid product in existence, including the ADA. This should be shoved in every endo's face. There are legal things on what reps can and cannot say (I found out it's actually extremely limited and if they were to start saying ultra rapid to an endo that'd be a huge nono) and the FDA is all too eager as we've seen in the past.
|
|
|
Post by mango on Jun 8, 2019 10:00:53 GMT -5
ST...$MNKD from Rose...."Thank you for your inquiry. You are correct. In Brazil, Afrezza is designated as an ultra rapid-acting mealtime insulin. In the US, Afrezza is designated as a rapid-acting inhaled insulin. We continue to pursue reclassification or creation of a new category with scientific data from trials." Holy chit. nice
|
|
|
Post by rtmd on Jun 8, 2019 10:16:56 GMT -5
Maybe it has something to do with their version of humulin R that is currently in trial: www.braziliantrials.com/index/view/ensaios/2052?page=2"Pharmacokinetics (PK) and pharmacodynamics (PD) study of InsuBiomm R (Regular Insulin) in comparison to Humulin R in Type 1 patients" Appear to be in a similar time frame.
|
|